Test Price
2,700 AED✅ Home Collection Available
Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel in UAE | 2,700 AED | DHA Approved
Executive Summary & Core Metrics
Core Metrics
- ✓Price: 2,700 AED (all‑inclusive, no hidden fees)
- ✓Turnaround Time: 4 working days (expedited processing)
- ✓Accuracy: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139)
- ✓Sample Types: Bone marrow aspirate and peripheral blood
- ✓Methodology: Conventional karyotyping (G‑banding) + FISH (targeted probes)
Service Benefits
- ✓Hospital Extraction Only: Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- ✓Clinical Guidance: Telephonic Post‑Test Clinical Guidance with DHA‑licensed Consultant Medical Geneticist for result interpretation
- ✓Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731
- ✓Regulatory Compliance: Full adherence to UAE Federal Decree‑Law No. 45 of 2021 (PDPL) and Federal Law No. 2 of 2019 for health data protection
Test Overview & Methodology
The Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel combines conventional karyotyping and FISH analysis on blood and bone marrow to detect specific chromosomal abnormalities such as t(9;22) (Philadelphia chromosome), t(12;21), and hyperdiploidy. These findings are critical for risk stratification and therapeutic decision‑making in pediatric and adult ALL, in accordance with current WHO 2022 classification and international guidelines.
| Feature | Our Integrated Panel (FISH + Karyotyping) | Conventional Karyotyping Alone |
|---|---|---|
| Diagnostic Precision | Dual‑method resolution detects cryptic translocations missed by karyotyping alone | May miss microdeletions or low‑level mosaicism |
| Methodology | FISH (targeted probes) + full karyotype (G‑banding) on blood and bone marrow | G‑band karyotyping only, limited to dividing cells |
| Turnaround Time | 4 working days (expedited processing) | Typical 7–10 days |
| Clinical Utility | Full WHO 2022 risk stratification, guides TKIs and HSCT decisions | Limited to large structural changes, insufficient for modern protocols |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403): Cytogenetic findings are a vital component of the ALL diagnostic puzzle, yet they must always be correlated with morphological, immunophenotypic, and molecular data to frame a complete clinical picture. This panel equips your oncology team with the chromosomal roadmap needed for contemporary risk‑adapted therapy, including eligibility for tyrosine kinase inhibitors and haematopoietic stem cell transplantation. Our team is available to discuss results and their implications directly with you and your referring physician.
Safety & Exclusion Criteria
Advisory & Contraindications
- Exclusion: Severe uncorrected coagulopathy (INR >1.5 or platelets <50,000/µL), active infection at the aspiration site.
- Medication Warning: Do not discontinue prescribed medication without consulting your doctor. Anticoagulants may require temporary adjustment under specialist supervision.
- ER Red Flags: Post‑procedure excessive bleeding, new fever >38.5°C, or intense pain unresponsive to standard analgesia warrant immediate hospital evaluation.
Clinical Safety & Consent Compliance
All procedures are performed in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability. Informed consent is obtained prior to any invasive sample collection, and patients are fully briefed on risks, benefits, and alternatives.
Patient FAQ & Clinical Guidance
1. What is the Acute Lymphoblastic Leukemia Cytogenetics Panel?
The panel identifies chromosomal abnormalities in leukemia cells to guide prognosis and treatment. By employing both conventional karyotyping and FISH on blood and bone marrow, the test detects hallmark aberrations such as the Philadelphia chromosome (t(9;22)) and t(12;21), enabling precise risk stratification and therapy selection in accordance with current WHO guidelines.
2. Is a bone marrow sample always required?
Yes, bone marrow sampling alongside blood is required for complete cytogenetic analysis in ALL. Bone marrow aspirate provides the optimal source of dividing leukemic cells for karyotyping, while peripheral blood can be used for FISH; the combination ensures a comprehensive cytogenetic profile. All sample collections are conducted within accredited hospital facilities under stringent sterile conditions.
3. How are results interpreted, and do I need a consultation?
Results are interpreted in correlation with clinical findings, and post‑test teleconsultation is provided by our DHA‑licensed Consultant Medical Geneticist. A comprehensive report details any detected chromosomal gains, losses, or translocations along with their prognostic significance. We strongly recommend scheduling the included post‑test clinical guidance to translate these findings into a personalised treatment strategy.
UAE Regulatory & Data Privacy Adherence
Your data is protected under UAE law. DNA Labs UAE complies fully with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic and clinical information is encrypted, access‑controlled, and processed solely for diagnostic purposes with your explicit consent. We maintain rigorous data governance protocols aligned with international best practices to ensure confidentiality and integrity of your health records.
For concerns regarding your data rights or to request access, rectification, or deletion of your personal information, please contact our Data Protection Officer at +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel |
| Price (AED) | 2,700 AED (includes hospital collection, analysis, and post‑test guidance) |
| Turnaround Time | 4 working days from sample receipt |
| Sample Type / Matrix | Bone marrow aspirate (preferred) and peripheral blood (acceptable) |
| Methodology Used | Conventional karyotyping (G‑banding) + FISH (targeted probes) |
| ICD-10-CM Code | C91.00 (Acute lymphoblastic leukemia not having achieved remission) |
| LOINC Code | 48801-6 – Leukemia/lymphoma cytogenetics panel – Blood or Bone marrow by FISH |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
For insurance pre‑approval or direct billing inquiries, contact our billing team via WhatsApp at +971 54 548 8731 or call our lab at 04‑1234567.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians